Assembly Biosciences (ASMB) Competitors $10.10 +0.09 (+0.90%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ASMB vs. NKTR, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRXShould you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry. Assembly Biosciences vs. Nektar Therapeutics Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Royalty Pharma Assembly Biosciences (NASDAQ:ASMB) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings. Which has better earnings and valuation, ASMB or NKTR? Assembly Biosciences has higher earnings, but lower revenue than Nektar Therapeutics. Assembly Biosciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAssembly Biosciences$28.52M2.64-$61.23M-$6.72-1.49Nektar Therapeutics$98.43M1.20-$276.06M-$0.59-1.08 Is ASMB or NKTR more profitable? Assembly Biosciences has a net margin of -144.05% compared to Nektar Therapeutics' net margin of -180.70%. Assembly Biosciences' return on equity of -121.46% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Assembly Biosciences-144.05% -121.46% -34.56% Nektar Therapeutics -180.70%-173.28%-46.31% Does the MarketBeat Community favor ASMB or NKTR? Nektar Therapeutics received 394 more outperform votes than Assembly Biosciences when rated by MarketBeat users. Likewise, 70.73% of users gave Nektar Therapeutics an outperform vote while only 58.65% of users gave Assembly Biosciences an outperform vote. CompanyUnderperformOutperformAssembly BiosciencesOutperform Votes24458.65% Underperform Votes17241.35% Nektar TherapeuticsOutperform Votes63870.73% Underperform Votes26429.27% Do analysts rate ASMB or NKTR? Assembly Biosciences currently has a consensus price target of $33.00, suggesting a potential upside of 229.01%. Nektar Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 607.10%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Nektar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of ASMB or NKTR? 19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 5.1% of Assembly Biosciences shares are owned by insiders. Comparatively, 3.7% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, ASMB or NKTR? Assembly Biosciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Does the media refer more to ASMB or NKTR? In the previous week, Nektar Therapeutics had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 3 mentions for Nektar Therapeutics and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.59 beat Nektar Therapeutics' score of 0.32 indicating that Assembly Biosciences is being referred to more favorably in the media. Company Overall Sentiment Assembly Biosciences Positive Nektar Therapeutics Neutral SummaryNektar Therapeutics beats Assembly Biosciences on 12 of the 19 factors compared between the two stocks. Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASMB vs. The Competition Export to ExcelMetricAssembly BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.26M$6.46B$5.31B$7.35BDividend YieldN/A3.22%5.47%4.31%P/E Ratio-1.496.9521.9417.82Price / Sales2.64231.00380.9497.68Price / CashN/A65.6738.3134.64Price / Book1.345.936.453.98Net Income-$61.23M$143.22M$3.22B$247.81M7 Day Performance10.46%4.28%5.85%3.19%1 Month Performance-6.17%-13.11%-9.58%-7.70%1 Year Performance-25.21%-8.51%11.85%1.49% Assembly Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASMBAssembly Biosciences3.9004 of 5 stars$10.03+0.2%$33.00+229.0%-25.2%$75.26M$28.52M-1.49100Short Interest ↓NKTRNektar Therapeutics4.0106 of 5 stars$0.60-2.2%$4.50+645.2%-48.7%$112.39M$98.43M-0.72220Analyst ForecastCPIXCumberland Pharmaceuticals1.0174 of 5 stars$4.19+3.2%N/A+197.5%$58.53M$37.87M-5.4480Short Interest ↓News CoveragePositive NewsGap DownLLYEli Lilly and Company4.7952 of 5 stars$753.54+2.9%$1,012.00+34.3%+15.9%$714.48B$45.04B64.3539,000News CoveragePositive NewsGap UpJNJJohnson & Johnson4.505 of 5 stars$154.08+1.5%$171.50+11.3%+6.4%$371.31B$88.82B23.17152,700Earnings ReportDividend IncreaseAnalyst ForecastOptions VolumeAnalyst RevisionABBVAbbVie4.9001 of 5 stars$178.97+2.2%$210.71+17.7%+3.8%$316.59B$56.33B74.5750,000Upcoming EarningsEx-DividendAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsMRKMerck & Co., Inc.4.9993 of 5 stars$79.00-0.2%$115.50+46.2%-38.0%$199.56B$64.17B11.7469,000Upcoming EarningsAnalyst ForecastPositive NewsPFEPfizer4.9986 of 5 stars$22.10+0.9%$31.07+40.6%-14.9%$125.34B$63.63B15.6783,000BMYBristol-Myers Squibb4.7289 of 5 stars$51.33+1.2%$57.67+12.3%+0.6%$104.44B$48.30B-11.6134,300Upcoming EarningsShort Interest ↓Analyst RevisionNews CoveragePositive NewsZTSZoetis4.5771 of 5 stars$150.66+0.8%$214.40+42.3%+1.5%$67.22B$9.26B27.5413,800News CoveragePositive NewsRPRXRoyalty Pharma4.5157 of 5 stars$32.29+1.1%$42.50+31.6%+15.4%$18.61B$2.26B22.2780News CoveragePositive News Related Companies and Tools Related Companies Nektar Therapeutics Alternatives Cumberland Pharmaceuticals Alternatives Eli Lilly and Company Alternatives Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol-Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASMB) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
